Clinical trials

2

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

MOTION Clinical Trial

Prospective, multicenter, two-arm, 2:1 randomized controlled trial (RCT) comparing the benefits in subjects with medial knee osteoarthritis who are treated with either the MISHA Knee System or with non-surgical treatment. This is the first randomized head-to-head study comparing outcomes from subjects treated with the MISHA Knee System.

Participants needed: 100
Trial details
Biological sex: AllType: InterventionalSponsor: MoximedUpdated: Jun 3, 2026Locations: 8
Eligibility criteria

Activity exacerbated knee pain isolated to the medial compartment and not global... [+2]

Large medial osteophyte(s) or considerable extruded meniscus that may interfere... [+7]

Status: Recruiting

MISHA Post-Market Clinical Study

Prospective evaluation of the safety and effectiveness of the MISHA Knee System. The study will collect data on the procedural and long-term adverse events, WOMAC pain and function scores, KSS satisfaction, subsequent surgical interventions, BMI levels, range of motion, UCLA activity level of the subjects, and perform radiographic/x-ray evaluations at clinical visits through 5 years post-procedure. The primary analysis of this study is freedom from device- and procedure-related SSIs at five (5) years post-implantation. This study will also assess device performance in subjects with intact and retained devices and subjects with devices removed prior to study termination and freedom from conversion to arthroplasty through 5 years. Study subjects will be followed over a five-year post-implant period.

Participants needed: 120
Trial details
Age: 25-65Biological sex: AllType: InterventionalSponsor: MoximedUpdated: Apr 1, 2026Locations: 3
Eligibility criteria

Subjects aged 25 to 65 years at time of index procedure [+4]

Large medial osteophyte(s) or considerable extruded meniscus that may interfere... [+7]